This case-control study examines whether individuals presenting with more advanced breast cancers at diagnosis were more likely to have prevalent cardiovascular disease compared with individuals with early-stage breast cancers at diagnosis.
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.
Who is a cancer survivor? Years ago, some suggested that the definition should only include people who were cancer-free for a minimum amount of time…
Join the Women in Cancer Surgery Work Group for an in-depth discussion of the hurdles surgeons face as they set up a translational research program,…
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Nivolumab plus ipilimumab–based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC. Here we report clinical outcomes from a pooled analysis…
What does the term “remission” actually mean? And how does it differ – if at all – from “no evidence of disease” or even “cancer-free?”…
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Moffitt’s SPARK, the Summer Program for the Advancement of Research Knowledge, is a sponsored internship program for undergraduates at the Moffitt Cancer Center in Tampa.
